Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Pharma Industry Analysis

UpdatedJun 28, 2026
DataAggregated Company Financials
Companies5
  • 7D8.0%
  • 3M36.0%
  • 1Y-25.3%
  • YTD-3.2%

Over the last 7 days, the Pharma industry has risen 8.0%, driven by gains from Novo Nordisk of 8.5%. In the same time, Stenocare was down 8.7%. In contrast, the industry has lost 25% in the last 12 months. Looking forward, earnings are expected to remain mostly flat in the next few years.

Industry Valuation and Performance

Has the Danish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 28 Jun 2026DKK 1.5tDKK 359.9bDKK 126.9b11.5x11.9x4.2x
Tue, 26 May 2026DKK 1.4tDKK 359.9bDKK 126.9b11.1x10.9x3.8x
Thu, 23 Apr 2026DKK 1.2tDKK 340.0bDKK 106.8b13.4x11.2x3.5x
Sat, 21 Mar 2026DKK 1.1tDKK 340.0bDKK 106.8b11.6x10.6x3.3x
Mon, 16 Feb 2026DKK 1.5tDKK 339.8bDKK 106.7b13.5x13.7x4.3x
Wed, 14 Jan 2026DKK 1.8tDKK 345.8bDKK 108.6b16.4x16.5x5.2x
Fri, 12 Dec 2025DKK 1.5tDKK 345.8bDKK 108.6b13.7x13.9x4.4x
Sun, 09 Nov 2025DKK 1.4tDKK 345.0bDKK 108.2b12.9x12.8x4x
Tue, 07 Oct 2025DKK 1.8tDKK 341.3bDKK 115.5b15.5x15.7x5.3x
Thu, 04 Sep 2025DKK 1.7tDKK 341.3bDKK 115.5b14.6x14.8x5x
Sat, 02 Aug 2025DKK 1.4tDKK 331.8bDKK 108.8b13.1x13.3x4.4x
Mon, 30 Jun 2025DKK 2.0tDKK 331.8bDKK 108.8b18.6x18.5x6.1x
Wed, 28 May 2025DKK 2.1tDKK 331.8bDKK 108.8b19.7x19.7x6.4x
Fri, 25 Apr 2025DKK 1.9tDKK 317.9bDKK 104.9b18x17.9x5.9x
Sun, 23 Mar 2025DKK 2.4tDKK 317.9bDKK 104.9b23.2x23x7.6x
Tue, 18 Feb 2025DKK 2.6tDKK 317.8bDKK 104.9b25x24.8x8.2x
Thu, 16 Jan 2025DKK 2.8tDKK 297.4bDKK 98.2b28.4x28.1x9.3x
Sat, 14 Dec 2024DKK 3.4tDKK 297.4bDKK 98.2b35.2x34.7x11.5x
Mon, 11 Nov 2024DKK 3.4tDKK 296.4bDKK 98.0b34.9x34.5x11.4x
Wed, 09 Oct 2024DKK 3.6tDKK 283.9bDKK 93.2b39.3x38.8x12.7x
Fri, 06 Sep 2024DKK 4.0tDKK 283.9bDKK 93.2b43.7x43x14.1x
Sun, 04 Aug 2024DKK 3.9tDKK 269.3bDKK 92.2b43.3x42.7x14.6x
Tue, 02 Jul 2024DKK 4.5tDKK 269.3bDKK 92.2b49.9x49.1x16.8x
Thu, 30 May 2024DKK 4.1tDKK 269.3bDKK 92.2b45.3x44.6x15.3x
Sat, 27 Apr 2024DKK 4.0tDKK 257.0bDKK 86.4b47.3x46.5x15.6x
Mon, 25 Mar 2024DKK 4.0tDKK 257.0bDKK 86.4b47.3x46.5x15.6x
Wed, 21 Feb 2024DKK 3.8tDKK 257.0bDKK 86.4b45x44.3x14.9x
Fri, 19 Jan 2024DKK 3.3tDKK 238.8bDKK 78.2b43.3x42.5x13.9x
Sun, 17 Dec 2023DKK 3.0tDKK 238.8bDKK 78.2b39.3x38.5x12.6x
Tue, 14 Nov 2023DKK 3.1tDKK 238.8bDKK 78.1b41.1x40.3x13.2x
Thu, 12 Oct 2023DKK 3.1tDKK 225.4bDKK 70.1b45.3x44.3x13.8x
Sat, 09 Sep 2023DKK 3.1tDKK 225.4bDKK 70.1b45.1x44x13.7x
Mon, 07 Aug 2023DKK 2.4tDKK 211.8bDKK 63.8b38.9x38x11.5x
Wed, 05 Jul 2023DKK 2.5tDKK 211.8bDKK 63.8b39.6x38.7x11.7x
Price to Earnings Ratio

38.7x


Total Market Cap: DKK 2.5tTotal Earnings: DKK 63.8bTotal Revenue: DKK 211.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Pharma Industry Price to Earnings3Y Average 29.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.9x which is lower than its 3-year average PE of 29.4x.
  • The 3-year average PS ratio of 9.6x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 19% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market2.91%
Healthcare7.00%
Pharma8.00%
Pharma8.00%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 317.958.5%
+DKK 110.7b		-27.3%PE11.5x
HLUN B H. LundbeckDKK 42.001.2%
+DKK 475.8m		17.5%PE11.2x
ALK B ALK-AbellóDKK 251.000.4%
+DKK 221.6m		35.5%PE43.4x
PEG Pharma Equity GroupDKK 0.090.9%
+DKK 982.0k		-31.0%PB4.3x

Latest News

ALK B
DKK 251.00
ALK-Abelló
7D
0.4%
1Y
35.5%
Narrative Update • Jun 26

ALK B: Paediatric Allergy Approvals Will Drive Future Immunotherapy Leadership

Analysts have raised their price target on ALK-Abelló from DKK 243 to DKK 305, citing the company's position as a global leader in allergy immunotherapy as a key factor in their updated view. What’s in the News for ALK-Abelló UK regulator MHRA granted marketing authorisation for EURneffy 1 mg, the first needle free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 to less than 30 kg, expanding ALK-Abelló’s emergency allergy treatment options in the UK.
NOVO B
DKK 317.95
Novo Nordisk
7D
8.5%
1Y
-27.3%
HLUN B
DKK 42.00
H. Lundbeck
7D
1.2%
1Y
17.5%
STENO
DKK 1.00
Stenocare
7D
-8.7%
1Y
72.4%
PEG
DKK 0.09
Pharma Equity Group
7D
0.9%
1Y
-31.0%